(PRVA) Privia Health - Ratings and Ratios
Primary Care, Value-Based Care, Provider Networks
PRVA EPS (Earnings per Share)
PRVA Revenue
Description: PRVA Privia Health
Privia Health Group Inc (NASDAQ:PRVA) is a US-based healthcare services company. To assess its investment potential, we need to examine its financial health and operational performance.
The companys income tax expense is a crucial aspect of its financials, as it directly impacts its net income. A thorough analysis of this component can reveal insights into Privias tax strategy and its effects on profitability.
Key Performance Indicators (KPIs) such as revenue growth, patient acquisition costs, and medical cost ratio are essential in evaluating Privias operational efficiency. The companys ability to manage these metrics will likely influence its future financial performance.
Economic drivers that may impact Privias business include changes in healthcare policy, reimbursement rates, and the overall demand for healthcare services. The companys exposure to these factors can affect its revenue and profitability.
With a market capitalization of approximately $2.3 billion, Privias stock is considered relatively liquid, with an average daily trading volume of around 895,000 shares. Its price-to-earnings ratio of 157.17 and forward P/E of 35.97 suggest that investors have high expectations for the companys future earnings growth.
To further evaluate the investment potential of PRVA, it is essential to analyze its return on equity (ROE) of 2.49%, which indicates that the company may not be generating sufficient returns on shareholder equity. A more in-depth examination of the companys financial statements and operational metrics is necessary to identify areas for improvement and potential opportunities for growth.
PRVA Stock Overview
| Market Cap in USD | 2,844m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2021-04-28 |
PRVA Stock Ratings
| Growth Rating | -20.2% |
| Fundamental | 69.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 0.59% |
| Analyst Rating | 4.57 of 5 |
PRVA Dividends
Currently no dividends paidPRVA Growth Ratios
| Growth Correlation 3m | 24.9% |
| Growth Correlation 12m | 37.2% |
| Growth Correlation 5y | -64.9% |
| CAGR 5y | -15.76% |
| CAGR/Max DD 3y | -0.28 |
| CAGR/Mean DD 3y | -0.40 |
| Sharpe Ratio 12m | 0.45 |
| Alpha | 0.02 |
| Beta | 0.960 |
| Volatility | 36.32% |
| Current Volume | 595.2k |
| Average Volume 20d | 595.2k |
| Stop Loss | 21.6 (-3.2%) |
| Signal | 0.49 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (14.8m TTM) > 0 and > 6% of Revenue (6% = 114.0m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -0.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.32% (prev 20.65%; Δ -2.32pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 91.9m > Net Income 14.8m (YES >=105%, WARN >=100%) |
| Net Debt (-383.5m) to EBITDA (30.1m) ratio: -12.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (128.4m) change vs 12m ago 2.50% (target <= -2.0% for YES) |
| Gross Margin 9.83% (prev 9.69%; Δ 0.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 161.7% (prev 157.4%; Δ 4.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 1.15
| (A) 0.27 = (Total Current Assets 883.0m - Total Current Liabilities 534.9m) / Total Assets 1.27b |
| (B) -0.14 = Retained Earnings (Balance) -172.3m / Total Assets 1.27b |
| (C) 0.02 = EBIT TTM 22.0m / Avg Total Assets 1.18b |
| (D) -0.32 = Book Value of Equity -171.1m / Total Liabilities 539.0m |
| Total Rating: 1.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.03
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 3.94% = 1.97 |
| 3. FCF Margin 5.10% = 1.27 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda 0.22 = 2.46 |
| 6. ROIC - WACC (= 2.08)% = 2.60 |
| 7. RoE 2.29% = 0.19 |
| 8. Rev. Trend 94.15% = 7.06 |
| 9. EPS Trend 19.57% = 0.98 |
What is the price of PRVA shares?
Over the past week, the price has changed by -4.74%, over one month by +4.45%, over three months by -2.49% and over the past year by +19.42%.
Is Privia Health a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PRVA is around 18.68 USD . This means that PRVA is currently overvalued and has a potential downside of -16.31%.
Is PRVA a buy, sell or hold?
- Strong Buy: 14
- Buy: 5
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PRVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.2 | 35.1% |
| Analysts Target Price | 30.2 | 35.1% |
| ValueRay Target Price | 21 | -5.8% |
Last update: 2025-09-05 04:56
PRVA Fundamental Data Overview
CCE Cash And Equivalents = 390.1m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 210.6364
P/E Forward = 35.9712
P/S = 1.4966
P/B = 4.1653
Beta = 0.806
Revenue TTM = 1.90b USD
EBIT TTM = 22.0m USD
EBITDA TTM = 30.1m USD
Long Term Debt = 4.14m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 2.50m USD (from shortTermDebt, last quarter)
Debt = 6.64m USD (Calculated: Short Term 2.50m + Long Term 4.14m)
Net Debt = -383.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.46b USD (2.84b + Debt 6.64m - CCE 390.1m)
Interest Coverage Ratio = unknown (Ebit TTM 22.0m / Interest Expense TTM 0.0)
FCF Yield = 3.94% (FCF TTM 96.9m / Enterprise Value 2.46b)
FCF Margin = 5.10% (FCF TTM 96.9m / Revenue TTM 1.90b)
Net Margin = 0.78% (Net Income TTM 14.8m / Revenue TTM 1.90b)
Gross Margin = 9.83% ((Revenue TTM 1.90b - Cost of Revenue TTM 1.71b) / Revenue TTM)
Tobins Q-Ratio = -14.38 (set to none) (Enterprise Value 2.46b / Book Value Of Equity -171.1m)
Interest Expense / Debt = 42.9k% (Interest Expense 2.85b / Debt 6.64m)
Taxrate = 38.84% (10.8m / 27.9m)
NOPAT = 13.5m (EBIT 22.0m * (1 - 38.84%))
Current Ratio = 1.65 (Total Current Assets 883.0m / Total Current Liabilities 534.9m)
Debt / Equity = 0.01 (Debt 6.64m / last Quarter total Stockholder Equity 682.9m)
Debt / EBITDA = 0.22 (Net Debt -383.5m / EBITDA 30.1m)
Debt / FCF = 0.07 (Debt 6.64m / FCF TTM 96.9m)
Total Stockholder Equity = 648.1m (last 4 quarters mean)
RoA = 1.17% (Net Income 14.8m, Total Assets 1.27b )
RoE = 2.29% (Net Income TTM 14.8m / Total Stockholder Equity 648.1m)
RoCE = 3.38% (Ebit 22.0m / (Equity 648.1m + L.T.Debt 4.14m))
RoIC = 2.08% (NOPAT 13.5m / Invested Capital 648.1m)
WACC = unknown (E(2.84b)/V(2.85b) * Re(9.55%)) + (D(6.64m)/V(2.85b) * Rd(none%) * (1-Tc(0.39)))
Shares Correlation 3-Years: 84.85 | Cagr: 0.26%
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.70% ; FCFE base≈92.5m ; Y1≈114.2m ; Y5≈194.8m
Fair Price DCF = 20.62 (DCF Value 2.53b / Shares Outstanding 122.7m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 19.57 | EPS CAGR: 28.67% | SUE: -1.36 | # QB: 0
Revenue Correlation: 94.15 | Revenue CAGR: 16.44% | SUE: N/A | # QB: None
Additional Sources for PRVA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle